Amneal Pharmaceuticals (AMRX) Total Current Liabilities (2017 - 2026)

Amneal Pharmaceuticals' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $728.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 32.33% year-over-year to $728.0 million in Q1 2026; TTM through Mar 2026 was $728.0 million, a 32.33% decrease from a year earlier, with the FY2025 full-year figure at $881.6 million, down 21.96% from the prior year.
• Total Current Liabilities slipped to $728.0 million in Q1 2026 per AMRX's latest filing, from $881.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $1.1 billion in Q4 2024 and bottomed at $602.0 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $846.6 million (2023), against an average of $887.2 million.
• Across the five-year window, Total Current Liabilities soared 47.59% in 2022 and sank 32.33% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $752.8 million in 2022, then climbed by 12.46% to $846.6 million in 2023, then jumped by 33.45% to $1.1 billion in 2024, then decreased by 21.96% to $881.6 million in 2025, then declined by 17.42% to $728.0 million in 2026.
• Per Business Quant, the three latest AMRX Total Current Liabilities figures stand at $728.0 million (Q1 2026), $881.6 million (Q4 2025), and $862.1 million (Q3 2025).